NTLA Intellia Therapeutics Inc.

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2023 financial results and operational highlights in a conference call on August 3, 2023, at 8 a.m. ET.

To join the call:

  • U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
  • Please visit this for a simultaneous live webcast of the call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at , beginning on August 3, 2023, at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of genome editing to create new classes of genetic medicine. Learn more at . Follow us on Twitter .

Intellia Contacts:

Investors:

Ian Karp

Senior Vice President, Investor Relations and Corporate Communications



Lina Li

Senior Director, Investor Relations and Corporate Communications





EN
27/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intellia Therapeutics Inc.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Intellia Therapeutics Inc: 1 director

A director at Intellia Therapeutics Inc bought 100,000 shares at 10.030USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

 PRESS RELEASE

Intellia Therapeutics Announces Second Quarter 2025 Financial Results ...

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections; Tracking to enroll at least 650 patients cumulatively by year-endExpanding total enrollment of the MAGNITUDE study to approximately 1,200 patients, subject to health authority review, with no expected impact on previous projected enrollment or financial runwayExpect to complete enrollment by first half 2026 in the global Phase...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch